Sign In
Buy SRPT
$16.66
+0.420 (+2.59%)
At Close: Jun 04, 2026
Sarepta Therapeutics (SRPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
07:01pm, Wednesday, 28'th Feb 2024
The headline numbers for Sarepta Therapeutics (SRPT) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall
Is It Too Late to Buy Sarepta Therapeutics Stock?
07:15am, Wednesday, 28'th Feb 2024
Sarepta Therapeutics faced some issues last year, but it earned approval for an important medicine. The biotech is on the verge of another key regulatory nod that should help improve its financial res
Why Earnings Season Could Be Great for Sarepta Therapeutics (SRPT)
09:51am, Tuesday, 27'th Feb 2024
Sarepta Therapeutics (SRPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Sarepta (SRPT) to Report Q4 Earnings: Will It Beat Estimates?
12:25pm, Wednesday, 21'st Feb 2024
Investors' focus will likely be on Sarepta's (SRPT) product sales of its recently-approved DMD gene therapy when it reports fourth-quarter earnings.
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
08:30am, Wednesday, 21'st Feb 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2023 financial results
Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
11:06am, Tuesday, 20'th Feb 2024
Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sarepta's (SRPT) DMD Drug sBLA Gets FDA's Priority Tag, Stock Up
07:31am, Monday, 19'th Feb 2024
Sarepta (SRPT) announces the FDA's acceptance of its efficacy supplement to the Elevidys BLA, seeking to expand the treatment label for its DMD drug. The stock gains 8%.
Sarepta Therapeutics (SRPT) Moves 7.8% Higher: Will This Strength Last?
04:31am, Monday, 19'th Feb 2024
Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the n
Why Sarepta Therapeutics Stock Is Soaring Today
11:23am, Friday, 16'th Feb 2024
The U.S. FDA accepted Sarepta's efficacy supplement filing for DMD gene therapy Elevidys. This filing could lead to the removal of age and ambulation restrictions for Elevidys.
U.S. FDA to not conduct advisers' meet for Sarepta's Duchenne gene therapy
07:23am, Friday, 16'th Feb 2024
Sarepta Therapeutics said on Friday that the U.S. FDA will not conduct a meeting of its advisers and will do a priority review for traditional approval of its gene therapy Elevidys for a muscle wastin
Gene therapy: Why does it cost millions for a single treatment?
07:01am, Thursday, 15'th Feb 2024
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology. The shot heard around the world in the medic
5 Biotech Stocks to Consider for Your Portfolio in 2024
10:00am, Tuesday, 13'th Feb 2024
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position SRPT, EXEL, IMCR,
1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock?
01:45am, Sunday, 11'th Feb 2024
PTC Therapeutics could soon lose one of its major products in the E.U. Sarepta Therapeutics competes in the same disease market as PTC.
PepGen soars on Sarepta Therapeutics' Duchenne drug phase 2 data
06:06am, Tuesday, 06'th Feb 2024
PepGen Inc. NASDAQ: PEPG is a clinical-stage biotech focused on developing therapies for rare neuromuscular and neurological genetic diseases like Duchenne muscular dystrophy (DMD). PepGen utilizes it
Sarepta says its experimental Duchenne drug more effective than older medicine
07:17am, Monday, 29'th Jan 2024
Sarepta Therapeutics said on Monday a mid-stage trial showed its experimental drug produced higher levels of a specific protein deficient in some patients with Duchenne muscular dystrophy (DMD), a mus
